Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5280079
Max Phase: Preclinical
Molecular Formula: C35H40ClN5O5
Molecular Weight: 646.19
Associated Items:
ID: ALA5280079
Max Phase: Preclinical
Molecular Formula: C35H40ClN5O5
Molecular Weight: 646.19
Associated Items:
Canonical SMILES: C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1Cl)C(=O)N1CCN(C(=O)[C@@H](C)NC(=O)c2cccc3ccccc23)CC1
Standard InChI: InChI=1S/C35H40ClN5O5/c1-3-31(42)37-18-9-8-17-30(39-32(43)23-26-12-5-7-16-29(26)36)35(46)41-21-19-40(20-22-41)34(45)24(2)38-33(44)28-15-10-13-25-11-4-6-14-27(25)28/h3-7,10-16,24,30H,1,8-9,17-23H2,2H3,(H,37,42)(H,38,44)(H,39,43)/t24-,30+/m1/s1
Standard InChI Key: RKRREHSILPLFDL-HLADLETHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 646.19 | Molecular Weight (Monoisotopic): 645.2718 | AlogP: 3.48 | #Rotatable Bonds: 13 |
Polar Surface Area: 127.92 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.56 | CX Basic pKa: | CX LogP: 3.14 | CX LogD: 3.14 |
Aromatic Rings: 3 | Heavy Atoms: 46 | QED Weighted: 0.19 | Np Likeness Score: -0.92 |
1. Cundy NJ, Arciszewski J, Gates EWJ, Acton SL, Passley KD, Awoonor-Williams E, Boyd EK, Xu N, Pierson É, Fernandez-Ansieta C, Albert MR, McNeil NMR, Adhikary G, Eckert RL, Keillor JW.. (2023) Novel irreversible peptidic inhibitors of transglutaminase 2., 14 (2.0): [PMID:36846375] [10.1039/d2md00417h] |
Source(1):